APC
SPRO icon

Aspire Private Capital’s Spero Therapeutics SPRO Stock Holding History

Aspire Private Capital’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$173 – 676
2022
Q4 		$173 Hold
100
– – ﹤0.01% 629
2022
Q3 		$0 Hold
100
– – ﹤0.01% 653
2022
Q2 		$0 Hold
100
– – ﹤0.01% 637
2022
Q1 		$1K Hold
100
– – ﹤0.01% 563
2021
Q4 		$2K Hold
100
– – ﹤0.01% 542
2021
Q3 		$2K Hold
100
– – ﹤0.01% 506
2021
Q2 		$1K Buy
+100
New +$1.4K ﹤0.01% 558

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aspire Private Capital's SPRO Position: Q1 2023 in Review

Aspire Private Capital sold out of Spero Therapeutics (SPRO) in Q1 2023, closing a stake of 100 shares — an estimated $173 sold.

Aspire Private Capital first reported a position in SPRO in Q2 2021 and held it in 7 quarters. The position peaked at $2K in Q4 2021. 48 funds tracked by Wall St. Rank hold SPRO as of Q1 2023.

  • Aspire Private Capital reported no remaining Spero Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Aspire Private Capital sold 100 Spero Therapeutics shares in Q1 2023, an estimated $173.
  • Aspire Private Capital first reported a position in Spero Therapeutics in Q2 2021 and held it in 7 quarters.
  • Aspire Private Capital's Spero Therapeutics position peaked at $2K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2023.

Based on Aspire Private Capital's 13F filing for Q1 2023, filed 3 May 2023.